PTPRC and neoplasm: We observed a significant increase in the percentage of circulating and tumor-infiltrating NK cells (gated as CD45+CD3-B220-NKp46+NK1.1+) in mice treated with Roscovitine plus anti-PD-1 compared to vehicle (Figures 2C, F), suggesting that the combination therapy enhances immune-mediated anti-tumor responses by augmenting both adaptive (T cell) and innate (NK cell) immunity, with pronounced effects in the tumor microenvironment.